Standout Papers

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarc... 2018 2026 2020 2023 348
  1. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus (2018)
    Manish A. Shah, Takashi Kojima et al. JAMA Oncology

Immediate Impact

2 by Nobel laureates 24 from Science/Nature 86 standout
Sub-graph 1 of 19

Citing Papers

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
2023 StandoutNature
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
2 intermediate papers

Works of Soonmo Peter Kang being referenced

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
2018 Standout
Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
2015

Author Peers

Author Last Decade Papers Cites
Soonmo Peter Kang 2163 768 598 657 64 2.8k
Albiruni R. Abdul Razak 1928 1075 349 622 95 3.4k
Simon Pernot 2156 1031 520 921 97 3.4k
Marina Tschaika 1617 661 653 523 37 2.2k
Giovanni Schinzari 1421 741 385 315 112 2.2k
Catherine Julié 1647 611 683 279 68 2.3k
Archie Tse 1936 932 340 299 58 3.2k
Steven J. Lemery 1726 812 460 586 64 3.1k
Jifang Gong 1651 880 504 361 143 2.7k
Tania Fleitas 1064 975 508 290 58 2.1k
Kun He 1955 1223 222 563 53 3.1k

All Works

Loading papers...

Rankless by CCL
2026